News & Updates

Opioid use ups healthcare use, costs in adults with PsA, AS

24 Oct 2024

Patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) who use opioids end up with higher healthcare utilization and costs compared with those who do not use opioids, reports a study.

Opioid use ups healthcare use, costs in adults with PsA, AS

24 Oct 2024

At-term live births possible in pregnant women with vasculitis

24 Oct 2024

Women with vasculitis who get pregnant can deliver live births at term, although flares or hospitalization due to vasculitis may occur during pregnancy, according to a study.

At-term live births possible in pregnant women with vasculitis

24 Oct 2024

Better ambulatory care can reduce ED visits by arthritic patients

23 Oct 2024 by

Rheumatology ambulatory care must adequately respond to the need of patients with inflammatory arthritis (IA) to reduce their visits to the emergency department (ED), suggests a study.

Better ambulatory care can reduce ED visits by arthritic patients

23 Oct 2024

DISCREET highlights apremilast potential for genital psoriasis

22 Oct 2024 by

Individuals with psoriasis creeping into their intimate areas may find relief from apremilast, as shown by the week-32 improvements in multiple disease parameters in the phase III DISCREET study.

DISCREET highlights apremilast potential for genital psoriasis

22 Oct 2024

Original New Drug Application Approvals by US FDA (1-15 October 2024)

22 Oct 2024

New drug applications approved by US FDA as of 1-15 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 October 2024)

22 Oct 2024

Original New Drug Application Approvals by US FDA (16-30 September 2024)

21 Oct 2024

New drug applications approved by US FDA as of 16-30 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 September 2024)

21 Oct 2024

Diffusion-based extended-release fluticasone propionate helps alleviate knee OA pain

19 Oct 2024

EP-104IAR, a diffusion-based long-acting formulation of fluticasone propionate for intra-articular injection, appears to produce meaningful reductions in knee osteoarthritis (OA) pain that last up to 14 weeks, according to data from a phase II SPRINGBOARD study.

Diffusion-based extended-release fluticasone propionate helps alleviate knee OA pain

19 Oct 2024

Secukinumab infusion shows therapeutic potential in psoriatic arthritis

16 Oct 2024

In the treatment of patients with active psoriatic arthritis (PsA), intravenous secukinumab appears to yield rapid and sustained improvements in clinical measures, with a safety profile consistent with that of the subcutaneous formulation, according to the phase III INVIGORATE-2 study.

Secukinumab infusion shows therapeutic potential in psoriatic arthritis

16 Oct 2024

Original New Drug Application Approvals by US FDA (1-15 September 2024)

09 Oct 2024

New drug applications approved by US FDA as of 1-15 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 September 2024)

09 Oct 2024

Long-term muscle relaxant benefits limited for certain conditions

08 Oct 2024

The long-term use of skeletal muscle relaxants (SMRs) for chronic pain is beneficial only in patients with painful spasms or cramps and neck pain but not in those with low back pain, fibromyalgia, and headaches, according to the results of a systematic review and meta-analysis.

Long-term muscle relaxant benefits limited for certain conditions

08 Oct 2024

News & Updates

Filter by Specialty:

Specialty:

Opioid use ups healthcare use, costs in adults with PsA, AS

Opioid use ups healthcare use, costs in adults with PsA, AS

At-term live births possible in pregnant women with vasculitis

At-term live births possible in pregnant women with vasculitis

Better ambulatory care can reduce ED visits by arthritic patients

Better ambulatory care can reduce ED visits by arthritic patients

DISCREET highlights apremilast potential for genital psoriasis

DISCREET highlights apremilast potential for genital psoriasis

Original New Drug Application Approvals by US FDA (1-15 October 2024)

Original New Drug Application Approvals by US FDA (1-15 October 2024)

Original New Drug Application Approvals by US FDA (16-30 September 2024)

Original New Drug Application Approvals by US FDA (16-30 September 2024)

Diffusion-based extended-release fluticasone propionate helps alleviate knee OA pain

Diffusion-based extended-release fluticasone propionate helps alleviate knee OA pain

Secukinumab infusion shows therapeutic potential in psoriatic arthritis

Secukinumab infusion shows therapeutic potential in psoriatic arthritis

Original New Drug Application Approvals by US FDA (1-15 September 2024)

Original New Drug Application Approvals by US FDA (1-15 September 2024)

Long-term muscle relaxant benefits limited for certain conditions

Long-term muscle relaxant benefits limited for certain conditions